Cramer's Morning Take: Healthcare 1/16/24

SPEAKER_1 (0:00)

As a person with a very deep voice, I'm hired all the time for advertising campaigns. But a deep voice doesn't sell B2B, and advertising on the wrong platform doesn't sell B2B either. That's why if you're a B2B marketer, you should use LinkedIn ads. LinkedIn has the targeting capabilities to help you reach the world's largest professional audience. That's right, over 70 million decision makers all in one place. All the big wigs, then medium wigs, also small wigs who are on the path to becoming big wigs.

Okay, that's enough about wigs. LinkedIn ads allows you to focus on getting your B2B message to the right people. So, does that mean you should use ads on LinkedIn instead of hiring me, the man with the deepest voice in the world?

Yes, yes it does. Get started today and see why LinkedIn is the place to be, to be. We'll even give you a $100 credit on your next campaign. Go to linkedin.com/results to claim your credit. That's linkedin.com/results.

Terms and conditions apply.

Jim Cramer (1:02)

Hey, it's Cramer and this is my morning take on the market from today's CNBC Investing Club Morning Meeting. We've got a soggy day today. Market opened down and then just heading lower, interest rates going the wrong way. To me, Jeff, this is a day of consolidation and even Magnificent 7 is being brought down to some degree and that's what I'm talking about Apple and Tesla.

Tesla has been weak, Apple started rolling over. So we're seeing back to where the market was say two months ago.

Jeff Marks (1:34)

Exactly. A lot of the stocks that melted up in November, December, they've been pulling back. You can see that in the Russell 2000

It was down about 1% today compared to a little bit of a decline in the S&P 500

But you know, Jim, you mentioned technology, Magnificent 7, they're having a nice start to the year, excluding Apple, Tesla. But another area that's been a focus of yours recently coming out of the JP Morgan Healthcare Conference is healthcare. We added a few names to the bullpen last Friday. In your story yesterday, you talked about some more ideas too, in addition to Abbott, Amgen, Novartis, Walgreens.

Jim Cramer (2:14)

I think that one of the things that's happened that people have to understand is we're making some breakthroughs with genetics. That's why you're starting to see all these really interesting drugs. That's Danaher, by the way, but people should remember that you need Danaher to do gene sequencing. But what I really like, and Jim Breyer talked about this morning on Squawk, and I had dinner with him and he confirmed it, that with AI and healthcare, you get to figure out, let's say there's like a trillion permutations to different kinds of cancer. Well, that's nothing for AI. They can go through a trillion in three minutes.

Humans, obviously, it takes years.

So you're able to accelerate the whole process of generative AI, solving and maybe getting cancer to being more manageable.

Jeff Marks (2:54)

Yeah, and I know you had a two-part interview with, what was it, Beckton Dickinson?

Jim Cramer (2:58)

Yeah, because Beckton Dickinson, I thought, was really crucial. They make all the injectors for the GLPs.

They also make a lot of, you know, make the catheters. But that's a company that Dan Hirsch should combine with.

Jeff Marks (3:11)

Yeah, and we'll look, you know, these are companies, they were all hit pretty hard last year. Didn't do much, but the earnings growth is still there if you back out all the COVID dynamics.

Jim Cramer (3:21)

It's all sentiment. It's all sentiment just keeping it down.

Start your day with my out book on the market every morning. Visit cnbc.com/morningtake to become a CNBC Investing Club member at a special rate today.

SPEAKER_4 (3:40)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC, NBC Universal, or their parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet, or another medium.

No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment, or strategy. You should be aware of the risk of loss in following any strategy or investment discussed in the content from Cramer. To view the full CNBC Investing Club Disclaimer, please visit cnbc.com forward slash investing club disclaimer.

SPEAKER_5 (4:23)

How do you land your dream job? It starts by acing the interview. Learn exactly what hiring managers are looking for with CNBC Make It's new career boosting online course. Get the limited time offer. Register now at cnbcmakeit.com/courses.